Month: March 2026

Glass House Brands Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in Glass House history Full year 2026 wholesale cannabis biomass production is forecasted to be approximately 1,000,000 pounds, up approximately 50% from 2025. Year-end 2025 cash and restricted cash balance was $23.4 million, forecasting year-end 2026 cash to exceed $50 million. Conference call to be held today March 24, 2026, at 5:00 p.m. ETLONG BEACH, Calif and TORONTO, March 24, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today reported financial...

Workhorse Group Sets Date for Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

Conference call scheduled for Tuesday, March 31, 2026 at 4:30 p.m. Eastern time DETROIT, March 24, 2026 (GLOBE NEWSWIRE) — Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse”) a North American OEM and provider of all-electric trucks, shuttles and buses, plans to conduct a conference call to discuss its fourth quarter and fiscal year 2025 results and business outlook on Tuesday, March 31, 2026, at 4:30 p.m. Eastern time. Prior to the conference call, Workhorse will issue its fourth quarter and fiscal year 2025 earnings press release. The press release may also be viewed on Workhorse’s website at ir.workhorse.com. To listen to the conference call webcast, please go to the Investor Relations section of Workhorse’s website. To listen via telephone, please call (877)-407-0789 (U.S.) or (201)-689-8562 (international). A telephonic replay...

Reed’s Reports Fourth Quarter and Full Year 2025 Results; Announces Leadership Transition

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

Profitable Growth Initiatives Lead to Sequential Quarterly Improvement Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) — Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months and 12 months ended December 31, 2025. Additionally, the Company announced that Neal Cohane has been appointed to serve as interim Chief Executive Officer and member of the board of directors, effective today. Former CEO and Board Member Cyril Wallace has stepped down. The board has begun conducting a search for a permanent CEO. Leadership Transition Cohane is a highly accomplished and seasoned retail leader. He brings decades of leadership experience across...

BioCardia Reports 2025 Business Highlights and Financial Results

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are provided below. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01) In parallel to advancing the regulatory discussions with the USA FDA and Japan PMDA on the potential market release of the CardiAMP System for the treatment...

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter...

BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial and Business HighlightsGenerated net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97% Completed the acquisition of the BioTissue Holdings Inc. surgical and wound assets in January 2026, significantly expanding the Company’s product portfolio, commercial footprint, and diversifying end markets into the hospital setting Integrated BioTissue’s experienced national sales force of approximately 20 direct sales representatives and managers, and more...

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 24, 2026. Posted in Earnings Releases And Operating Results.

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsDelivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024; Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear; Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer, effective March 1, 2026; and Closed on a credit facility for up to $70.0 million from Perceptive Advisors (“Perceptive”). The Perceptive...

Bright Mountain Media, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

Written by Customer Service on March 24, 2026. Posted in Public Companies.

Full-year 2025 revenue increased by $2.5 million to $59.2 million compared to $56.7 million for the full-year of 2024.Boca Raton, FL, March 24, 2026 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a global holding company with current investments in digital publishing, advertising technology, consumer insights, creative services, and media services, today announced its financial results for the fourth quarter and year ended December 31, 2025. Matt Drinkwater, CEO of Bright Mountain Media, shared an update on the Company’s fourth quarter performance, highlighting solid progress despite broader market pressures. “Year-to-date revenue has reached $59.2 million, an increase of $2.5 million compared to the same period in 2024”, he reported. “While our fourth...

Draganfly Reports Record Q4 and Year End Results

Written by Customer Service on March 24, 2026. Posted in Public Companies.

Saskatoon, SK., March 24, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its fourth quarter and fiscal 2025 financial results. Revenue for the fourth quarter was up 18.5% year over year. Total 2025 revenue increased 17.8%. Key Financial Highlights for 2025:‎Total revenue for the year ended December 31, 2025, was $7,731,163, an increase of 17.8% from the prior year. Product sales increased $1,501,339, from $5,368,476 in 2024 to $6,869,815 in 2025, an increase of 28.0% year over year. Services revenue decreased $331,231or 27.7% from $1,192,579 in 2024 to $861,348 in 2025. Gross Profit was $1,321,336, a decrease of $76,868 or 5.5% from the prior year. As a percentage of sales,...

Update 1: Air Canada Provides Additional Information on Air Canada Express Flight AC8646

Written by Customer Service on March 24, 2026. Posted in Public Companies.

MONTRÉAL, March 24, 2026 (GLOBE NEWSWIRE) — Air Canada is providing the following update on the accident involving an Air Canada Express Mitsubishi CRJ900 upon landing at New York LaGuardia on March 22, 2026 around 11:30 p.m. Flight AC8646, operated by Air Canada Express carrier Jazz Aviation LP (Jazz), originated from Montréal. Air Canada confirms that the passenger list indicates the airplane was carrying 72 passengers and four crew members. The Captain and First Officer of the flight died in the accident. “On behalf of everyone at Air Canada, I want to express my deep sympathies to everybody affected, and my deepest condolences to the family and friends of the two Jazz pilots who tragically lost their lives. We remain focused on the needs of our passengers and the Jazz crew members, along with their families and loved ones....

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals